placeholder image
G. P. Forlenza All authors
About
Publications While At 开云体育
selected publications
Journal Article
  • Glycemic outcomes persist for up to 2 years in very young children with the Omnipod(庐) 5 Automated Insulin Delivery System. 
    Diabetes Technology & Therapeutics. 2024
  • Increase access, reduce disparities: recommendations for modifying medicaid CGM coverage eligibility criteria. 
    Journal of Diabetes Science and Technology. 2024
  • Psychosocial outcomes with the Omnipod庐 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. 
    Diabetes, Obesity & Metabolism. 2024
  • Two years with a tubeless automated insulin delivery system: a single-arm multicenter trial in children, adolescents, and adults with Type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2024
  • Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. 
    Endocrine Reviews. 2023
  • Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial. 
    Diabetes Technology & Therapeutics. 2023
  • Safety and glycemic outcomes during the MiniMed(TM) advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2023
  • How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: findings from the first investigation with the Omnipod庐 5 System. 
    Diabetes Research and Clinical Practice. 2022
  • Real-world evidence supporting Tandem Control-IQ Hybrid Closed-Loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations. 
    Diabetes Technology & Therapeutics. 2022
  • Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial. 
    Diabetes care. 2022
  • First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2021
  • Lost in translation: a disconnect between the science and Medicare coverage criteria for continuous subcutaneous insulin infusion. 
    Diabetes Technology & Therapeutics. 2021
  • Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. 
    Diabetes care. 2021
    • Review
  • Coverage for continuous glucose monitoring for individuals with type 2 diabetes treated with nonintensive therapies: an evidence-based approach to policymaking [review]. 
    Diabetes Technology & Therapeutics. 2023
    • Abstract
  • First home evaluation of the Omnipod Horizon automated glucose control system at specific glucose targets in children with type 1 diabetes [abstract]. 
    Diabetes. 2020
    • Contact
    full name
  • G. P. Forlenza
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration